Abstract:ID 92341 Poster Board 545 As one of the most successful set of targets for therapeutic development, GPCRs are activated by diverse array of ligands to induce signaling through multiple distinct pathways, yielding varied biological and physiological responses.The pharmacological concept of biased signaling (functional selectivity) describes the ability of select ligands to preferentially activate one receptor-mediated signaling pathway over others. The development of functionally selective ligands holds significant implications for the development of drugs with fewer side effects. Antibodies (Abs) are useful tools for targeting cell surface proteins; however, developing signaling competent GPCR-targeted Abs remains challenging and is often unsuccessful. Camelid single domain antibodies (or nanobodies, Nbs) have been shown to target epitopes in GPCRs not accessible to conventional Abs. However, it remains difficult to identify Nbs that can directly activate GPCR signaling. We developed a unique methodology in our lab to link PTHR1-binding Nbs with synthetic ligands to provide semi-synthetic conjugates that directly modulate GPCR function to overcome this hurdle. Nb-ligand conjugates were prepared through a combination of enzymatic protein labeling, solid-phase peptide (ligand) synthesis, and chemoselective conjugation chemistry. Unlike conventional approaches that modify the core ligand structure, our strategy involves conjugating the ligand to a nanobody that tethers it to the targeted receptor. The activity of Nb-ligand conjugates were assessed in a series of pharmacological assay, including cAMP production, G-protein dissociation, and β-arrestin translocation assays. The linkage of a weakly active PTHR1 ligand fragment (PTH 1-11 ) to a Nb that bound to PTHR1 extracellular domain caused a substantial enhancement in potency for signaling through the G αs pathway. We also assessed duration of signaling in a cAMP "washout" assay. Results revealed that Nb-peptide conjugates induced prolonged cAMP responses upon ligand washout relative to an analogue of a human PTHR1 drug PTH 1-11 . In contrast, these conjugates displayed a drastically impaired capacity to induce recruitment of β-arrestin to the plasma membrane or to early endosomes or to signal via G αq. These findings mark the Nb-PTH 1-11 conjugates as the most biased agonist of PTHR1 reported to date. We also performed mechanistic studies of the origin of bias, revealing that the Nb-PTH 1-11 conjugates can activate signaling through a mode that involves two receptor protomers (activation in trans ). This mechanism is qualitatively distinct from that of conventional PTHR1 ligands such as PTH 1-34 or PTH 1-11 . The platform described here has the potential to advance our understanding of diseases associated with PTHR1 by enabling selective modulation of individual signaling pathways. Work is underway to expand this platform to generate Nb-based biased agonists of other GPCRs including opioid receptors. Facile generation of biased agonists offers the prospect of probing the utility of pathway-selective signaling for the treatment GPCR-associated diseases. This research was supported by the Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Single-chain nanobody inhibition of Notch and avidity enhancement utilizing the β-pore forming toxin Aerolysin

Therapeutic antibody targeting of individual Notch receptors

Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3

Characterization of a nanobody-epitope tag interaction and its application for receptor engineering

Engineering synthetic agonists for targeted activation of Notch signaling

Dynamic Regulation of Notch 1 and Notch 2 Surface Expression During T Cell Development and Activation Revealed by Novel Monoclonal Antibodies

Engineering of an Enhanced Synthetic Notch Receptor by Reducing Ligand-Independent Activation

Synthetic nanobodies as angiotensin receptor blockers.

Development of a synthetic library of humanized nanobodies for targeted IL-6 inhibition

Nanobody Tethering Enables Highly Biased Agonism for GPCR Ligands

Development of nanobodies against Staphylococcus enterotoxin B through yeast surface display

Discovery and pharmacological characterization of nanobodies acting as potent positive allosteric modulators of the calcium-sensing receptor

Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module

Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation

Bispecific Engineered Antibody Domains (nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn.

Enhancing Anti-Cancer Immune Response by Acidosis-Sensitive Nanobody Display

Aβ-targeting synNotch Receptor for Alzheimer′s Disease: Expanding Applications to Extracellular Protein Aggregates

Nanobody engineering for SARS-CoV-2 neutralization and detection

Semi-synthetic nanobody-ligand conjugates exhibit tunable signaling properties and enhanced transcriptional outputs at neurokinin receptor-1